Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study.
HIV
direct-acting antiviral
hepatitis C virus
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
11
11
2018
accepted:
25
02
2019
entrez:
6
4
2019
pubmed:
6
4
2019
medline:
6
4
2019
Statut:
epublish
Résumé
Direct-acting antiviral (DAA) therapy have been shown to be highly successful in clinical trials and observational studies, but less is known about treatment success in patients with a high burden of comorbid conditions, including mental health and substance use disorders. We evaluated DAA effectiveness across a broad spectrum of patients with human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection in routine clinical care, including those with psychosocial comorbid conditions. The primary end point was sustained virologic response (SVR), defined as HCV RNA not detected or <25 IU/mL ≥10 weeks after treatment. We calculated SVR rates and 95% confidence intervals (CIs) in a modified intent-to-treat analysis. We repeated this analysis after multiply imputing missing SVR values. Among 642 DAA-treated patients, 536 had SVR assessments. The median age was 55 years; 79% were men, 59% black, and 32% white. Cirrhosis (fibrosis-4 index>3.25) was present in 24%, and 17% were interferon treatment experienced; 96% had genotype 1 infection and 432 (81%) had received ledipasvir-sofosbuvir. SVR occurred in 96.5% (95% CI, 94.5%-97.9%). Patients who were black, treatment experienced, or cirrhotic all had SVR rates >95%. Patients with depression and/or anxiety, psychotic disorder, illicit drug use, or alcohol use disorder also had high SVR rates, ranging from 95.4% to 96.8%. The only factor associated with lower SVR rate was early discontinuation (77.8%; 95% CI, 52.4%-93.6%). Similar results were seen in multiply imputed data sets. Our study represents a large multicenter examination of DAA therapy in HIV/HCV-coinfected patients. The broad treatment success we observed across this diverse group of patients with significant comorbid conditions is highly affirming and argues for widespread implementation of DAA therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Direct-acting antiviral (DAA) therapy have been shown to be highly successful in clinical trials and observational studies, but less is known about treatment success in patients with a high burden of comorbid conditions, including mental health and substance use disorders. We evaluated DAA effectiveness across a broad spectrum of patients with human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection in routine clinical care, including those with psychosocial comorbid conditions.
METHODS
METHODS
The primary end point was sustained virologic response (SVR), defined as HCV RNA not detected or <25 IU/mL ≥10 weeks after treatment. We calculated SVR rates and 95% confidence intervals (CIs) in a modified intent-to-treat analysis. We repeated this analysis after multiply imputing missing SVR values.
RESULTS
RESULTS
Among 642 DAA-treated patients, 536 had SVR assessments. The median age was 55 years; 79% were men, 59% black, and 32% white. Cirrhosis (fibrosis-4 index>3.25) was present in 24%, and 17% were interferon treatment experienced; 96% had genotype 1 infection and 432 (81%) had received ledipasvir-sofosbuvir. SVR occurred in 96.5% (95% CI, 94.5%-97.9%). Patients who were black, treatment experienced, or cirrhotic all had SVR rates >95%. Patients with depression and/or anxiety, psychotic disorder, illicit drug use, or alcohol use disorder also had high SVR rates, ranging from 95.4% to 96.8%. The only factor associated with lower SVR rate was early discontinuation (77.8%; 95% CI, 52.4%-93.6%). Similar results were seen in multiply imputed data sets.
CONCLUSIONS
CONCLUSIONS
Our study represents a large multicenter examination of DAA therapy in HIV/HCV-coinfected patients. The broad treatment success we observed across this diverse group of patients with significant comorbid conditions is highly affirming and argues for widespread implementation of DAA therapy.
Identifiants
pubmed: 30949539
doi: 10.1093/ofid/ofz100
pii: ofz100
pmc: PMC6441587
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz100Subventions
Organisme : NIAID NIH HHS
ID : R24 AI067039
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027763
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIAAA NIH HHS
ID : U01 AA020793
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050410
Pays : United States
Références
Clin Infect Dis. 2001 Aug 15;33(4):562-9
pubmed: 11462196
Clin Infect Dis. 2002 Mar 15;34(6):831-7
pubmed: 11833007
Addiction. 2002 Sep;97(9):1183-94
pubmed: 12199834
AIDS. 2005 Oct;19 Suppl 3:S99-105
pubmed: 16251836
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Alcohol Clin Exp Res. 2007 Jul;31(7):1208-17
pubmed: 17451397
Annu Rev Med. 2008;59:473-85
pubmed: 18186707
Int J Epidemiol. 2008 Oct;37(5):948-55
pubmed: 18263650
Am J Epidemiol. 2010 Nov 1;172(9):1070-6
pubmed: 20841346
Clin Infect Dis. 2012 Jan 1;54(1):141-7
pubmed: 22042879
Clin Infect Dis. 2012 Jul;55 Suppl 1:S33-42
pubmed: 22715212
J Infect Dis. 2013 Mar;207 Suppl 1:S19-25
pubmed: 23390301
AIDS Res Ther. 2013 Mar 28;10(1):9
pubmed: 23537147
Clin Infect Dis. 2013 Aug;57 Suppl 2:S80-9
pubmed: 23884071
AIDS Care. 2014;26(9):1178-85
pubmed: 24601687
HIV Med. 2015 Apr;16(4):230-9
pubmed: 25522874
JAMA. 2015 Mar 24-31;313(12):1223-31
pubmed: 25706092
N Engl J Med. 2015 Aug 20;373(8):714-25
pubmed: 26196502
N Engl J Med. 2015 Aug 20;373(8):705-13
pubmed: 26196665
Clin Infect Dis. 2016 Apr 1;62(7):919-926
pubmed: 26743093
AIDS Patient Care STDS. 2016 Feb;30(2):51-5
pubmed: 26744994
Ann Hepatol. 2016 Mar-Apr;15(2):154-9
pubmed: 26845592
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
Hepatology. 2016 Aug;64(2):405-14
pubmed: 27115523
Ann Intern Med. 2016 Nov 1;165(9):625-634
pubmed: 27537841
Clin Infect Dis. 2016 Dec 1;63(11):1405-1411
pubmed: 27553375
AIDS Behav. 2017 Jul;21(7):1878-1884
pubmed: 28035496
Clin Infect Dis. 2017 Jun 15;64(12):1711-1720
pubmed: 28199525
AIDS. 2017 Jun 1;31(9):1253-1260
pubmed: 28358742
Open Forum Infect Dis. 2017 Apr 05;4(2):ofx062
pubmed: 28534036
Hepatology. 2017 Nov;66(5):1402-1412
pubmed: 28608973
Ann Intern Med. 2017 Sep 5;167(5):311-318
pubmed: 28785771
Hepatology. 2018 Mar;67(3):847-857
pubmed: 29108121
Lancet Infect Dis. 2018 Feb;18(2):215-224
pubmed: 29153265
HIV Med. 2018 Apr;19(4):299-307
pubmed: 29368456
J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051
pubmed: 29633559
Ann Intern Med. 2018 Sep 18;169(6):376-384
pubmed: 30140916